Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

Katz, L. Jay; Cohen, John; Batoosingh, Amy L.; Félix, Carlos Roberto; Shu, Vincent; Schiffman, Rhett M.

doi:10.1016/j.ajo.2009.12.003

Cited by 80 publications

(93 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the fact that our results closely parallel to those of an important double-masked clinical trial 12 suggests that this may have not greatly impacted the results.…”

Section: Discussionsupporting

confidence: 58%

“…10,11 Bimatoprost 0.03% ophthalmic solution (Lumigan; Allergan, Inc., Irvine, CA, USA) was introduced into ophthalmic practice in 2001. 12 It has been demonstrated to be safe and effective in lowering IOP by 6.5-8.9 mm Hg over the long term in glaucoma and ocular hypertension (OHT). [13][14][15][16][17] However, bimatoprost 0.03% eye drop is burdened with some side effects.…”

Section: Introductionmentioning

confidence: 99%

“…Kats et al 12 have recently demonstrated that bimatoprost 0.01% is equivalent to bimatoprost 0.03% in lowering IOP throughout 12 months of treatment with less associated incidence of side effects such as conjuctival hyperemia. However, clinical symptoms and in vivo confocal microscopy (IVCM) findings have not been investigated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Figus

Nardi

Piaggi

et al. 2014

Eye

View full text Add to dashboard Cite

Results Global clinical score (the sum of pruritus, stinging/burning, blurred vision, sticky eye sensation, eye dryness sensation, and foreign body sensation) significantly decreased in the bimatoprost 0.01% group from baseline 4.7±3.8 to 2.9±2.3 (Po0.001) and 2.5±2.0 (Po0.001) at 6-month and 12-month follow-ups, respectively. Comparison between groups showed differences at both follow-up visits (P ¼ 0.003 and Po0.001, respectively). In vivo confocal microscopy revealed a significant increase in goblet cell density in the bimatoprost 0.01% group compared with the bimatoprost 0.03% group (Po0.001 at both follow-up visits). All functional parameters and conjunctival hyperemia improved in the bimatoprost 0.01% group at each follow-up visit (Po0.05) and in comparison with bimatoprost 0.03% (Po0.05). ConclusionThe results of this trial suggest that bimatoprost 0.01% eye drops seem to decrease the ocular discomfort with respect to bimatoprost 0.03% eye drops.

show abstract

“…However, the fact that our results closely parallel to those of an important double-masked clinical trial 12 suggests that this may have not greatly impacted the results.…”

Section: Discussionsupporting

confidence: 58%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Figus

Nardi

Piaggi

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…Recently, Oddone et al showed that bimatoprost 0.01%, which was developed to decrease local adverse effects including conjunctival hyperemia, eyelash growth, and skin pigmentation, 20) did not alter the nocturnal blood pressure after 8-week clinical trials. 9) Bimatoprost-related blood pressure elevation was not examined in some clinical trials for 0.03% bimatoprost.…”

Section: Discussionmentioning

confidence: 99%

Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases

Ohyama

Kawakami

Inoue

2017

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Topical prostaglandin F2α (PGF2α) analogs are widely used as the first line of therapy for glaucoma. Systemic PGF2α is suggested to increase blood pressure. Some ophthalmic formulations with β-receptor blocking or α-receptor stimulating actions are reported to cause systemic adverse events such as a decrease in heart rate and blood pressure. The objective of this study was to evaluate the association between topical Key words prostaglandin F2α analog; blood pressure elevation; spontaneous reporting database; adverse event; reporting odds ratio Glaucoma is a progressive, chronic condition prevalent worldwide that causes damage to the optic nerve, resulting in irreversible visual impairment and blindness. Based on the status of the internal drainage system, this condition is divided into two major subtypes i.e., open angle and angle closure.1) Reducing intraocular pressure (IOP) is one of the best ways to prevent the development of glaucoma, although there is a kind of open angle glaucoma in which optic neuropathy occurs without IOP exceeding the normal range. The approximate number of glaucoma patients was 60.5 million in 2010 and is estimated to increase to 79.6 million by 2020.2)

show abstract

“…Bimatoprost 0.01% (Lumigan* 0.01%), a new ophthalmic formulation, offers equivalent IOP-lowering efficacy to bimatoprost 0.03% (Lumigan* 0.03%), coupled with enhanced safety and tolerability 35 . The formulations are physically indistinguishable and differ only in the concentrations of bimatoprost (0.01% and 0.03%) and benzalkonium chloride (0.02% in bimatoprost 0.01%, 0.005% in bimatoprost 0.03%), a commonly used preservative that also can increase the corneal penetration 36 and intraocular bioavailability of topically applied medication.…”

Section: Introductionmentioning

confidence: 99%

Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions

Campbell

Schwartz

LaBounty³

et al. 2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

Cited by 80 publications

References 29 publications

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients

Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases

Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions

Contact Info

Product

Resources

About